![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » Lilly’s Lung Cancer Drug Wins EU Approval
Lilly’s Lung Cancer Drug Wins EU Approval
March 1, 2016
Eli Lilly’s lung cancer drug Portrazza has received a thumbs-up from EU health officials.
The drug was approved for use in conjunction with gemcitabine and cisplatin chemotherapy in patients with metastatic epidermal growth factor receptor expressing squamous non-small cell lung cancer who have not received prior chemotherapy.
The approval was backed by data from the Phase 3 SQUIRE trial, which revealed a median survival of 11.5 months versus 9.9 months for patients who received chemotherapy alone.
Necitumumab is the first biologic to receive marketing authorization in the EU as a first-line treatment choice for this indication, the company says.
Upcoming Events
-
21Oct